Bayer Aspirin Gets Its Second Wind

摘要

When Bayer executives talk about the products that will shape the future of their pharmaceutical unit, the drug names they cite sound like comic book villains: Xarelto, VEGF-Trap Eye, and Nexavar. Yet so far this year, Bayer's top performer is a surprising wonder drug from a bygone era: aspirin. The medicine patented under the last Kaiser has become the longlagging pharmaceutical unit'